Clinical Trials Logo

Clinical Trial Summary

Exploring the efficacy and safety of Toripalimab with Rituximab for treatment of relapsed refractory CD20 positive diffuse large B-cell lymphoma.


Clinical Trial Description

Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Rituximab is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC). These two drugs may have a synergistic effect on anti-tumor. The purpose of this study is to determine whether Toripalimab with Rituximab is effective and safe for treatment of relapsed refractory CD20 positive diffuse large B-cell lymphoma. This is an exploratory small sample, phase II, single-center clinical trial, which is going to enroll 20 participants. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04425824
Study type Interventional
Source Chinese Academy of Medical Sciences
Contact Yan Qin, doctor
Phone 13601282738
Email qinyan66@vip.sina.com
Status Not yet recruiting
Phase Phase 2
Start date June 15, 2020
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Recruiting NCT05823701 - Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients Phase 2
Completed NCT01691898 - A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Recruiting NCT03656835 - Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma N/A
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Active, not recruiting NCT02060656 - Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND) Phase 2
Active, not recruiting NCT01653067 - STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma Phase 2
Enrolling by invitation NCT00846157 - Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients Phase 3
Completed NCT00440583 - The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP Phase 2
Completed NCT01851551 - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL Phase 1/Phase 2
Recruiting NCT04981795 - realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Completed NCT01186978 - Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma N/A
Completed NCT01197560 - Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Phase 2/Phase 3
Recruiting NCT03246906 - Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Phase 2
Not yet recruiting NCT05990985 - The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. N/A
Completed NCT02890602 - Erythropoietin for Management of Anemia Caused by Chemotherapy Phase 2
Completed NCT03630159 - Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients Phase 1
Active, not recruiting NCT04529772 - A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) Phase 3
Active, not recruiting NCT02900651 - Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies Phase 1
Active, not recruiting NCT02481310 - Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma Phase 1/Phase 2